In vitro metabolism of the new anxiolytic agent, RWJ-52763 in human hepatic S9 fraction-API-MS/MS identification of metabolites.

@article{Wu2003InVM,
  title={In vitro metabolism of the new anxiolytic agent, RWJ-52763 in human hepatic S9 fraction-API-MS/MS identification of metabolites.},
  author={Wu Nan Wu and Linda A. Mckown and Allen B. Reitz},
  journal={Journal of pharmaceutical and biomedical analysis},
  year={2003},
  volume={31 1},
  pages={
          95-102
        }
}
The in vitro metabolism of the anxiolytic agent, RWJ-52763 was studied after incubation with human hepatic S9 fraction in the presence of an NADPH-generating system. Unchanged RWJ-52763 (64% of the sample) plus six metabolites (M1-M6) were profiled, quantified, and tentatively identified on the basis of API-MS/MS data. The metabolic pathways for RWJ-52763 are proposed, and the two metabolic pathways are: (1) N/O-dealkylation, and (2) phenylhydroxylation. Pathway 1 formed a major N-dealkylated… Expand
Human hepatic metabolism of the anxiolytic agent, RWJ-51521 — API-MS/MS identification of metabolites
TLDR
The In vitro metabolism of the anxiolytic agent, RWJ-51521 was conducted after incubation with human hepatic S9 fraction in the presence of an NADPH-generating system and 4 proposed metabolic pathways were proposed. Expand
Metabolism of the new anxiolytic agent, a pyrido[1,2-]benzimidazole (PBI) analog (RWJ-53050), in rat and human hepatic S9 fractions, and in dog; identification of cytochrome p450 isoforms mediated in the human microsomal metabolism
TLDR
In vitro and in vivo metabolism of RWJ-53050, an anxiolytic agent, was investigated after incubation with rat and human hepatic S9 fractions, and human microsomes containing individual human CYP isoforms. Expand
Fast LC/MS in the analysis of small molecules
TLDR
An examination of the current state of the literature, relating to "fast LC/MS", should serve well to those new toLC/MS, and should help them in the development of fast LC/ MS methods that are effective in terms of both the chromatography and the utilization of the mass spectrometer. Expand
Cycloaddition of 2-acylmethyl-1H-benzimidazoles to 4-arylidene-1,3-oxazol-5-ones
Cycloaddition of 2-phenacyl-1H-benzimidazole to 2-phenyl-or 2-methyl-4-arylidene-1,3-oxazol-5-ones occurs regioselectively to form the previously unknownExpand
Synthesis of pyrido[1,2-a]benzimidazoles from 2-acylmethyl-1H-benzimidazoles
Methods are proposed for the synthesis of previously unknown pyrido[1,2-a]benzimidazoles via the cyclocondensation of 2-acylmethyl-1H-benzimidazoles with malononitrile, triethylorthoformate ester, orExpand
Optimization in Drug Discovery
Optimization in drug discovery , Optimization in drug discovery , کتابخانه مرکزی دانشگاه علوم پزشکی تهران

References

SHOWING 1-3 OF 3 REFERENCES
Potential anxiolytic agents. 2. Improvement of oral efficacy for the pyrido[1,2-a]benzimidazole (PBI) class of GABA-A receptor modulators
Abstract We have further explored the structure-activity relationships of pyrido[1,2- a ]benzimidazole (PBI) derivatives (viz. prototype 1 ), a novel series of central GABA-A receptor modulators,Expand
Potential anxiolytic agents. 3. Novel A-ring modified pyrido[1,2-a]benzimidazoles.
TLDR
A-ring benzo-fused derivative 7 exhibited potent activity, as did the 6- and 7-pyrido compounds 3 and 4. Expand